Welcome to the AML (Acute Myeloid Leukemia) Clinical Trial at MHOA in New York City
Now enrolling patients for a phase 2/3 clinical study for the treatment of AML patients with FLT3 mutations who are not eligible for intensive induction therapy.
The study will evaluate treatments with:
ASP2215 Plus Azacitidine
Gilteritinib has demonstrated inhibitory activity against FLT3 internal tandem duplication (ITD), as well as tyrosine kinase domain (TKD), two common types of FLT3 mutations that are seen in 1/3 of patients with Acute Myeloid Leukemia.
MHOA Principle Investigator
Alec Goldenberg, M.D.